<i>Clostridioides difficile</i> infection is a global public health threat. Extensive <i>in vitro</i> assays using clinical isolates have identified micrococcin P2 (MP2, <b>1</b>) as a particularly effective anti-<i>C. difficile</i> agent. MP2 possesses a mode of action that differs from other antibiotics and pharmacokinetic properties that render it especially promising. Its time-kill studies have been investigated using hypervirulent <i>C. difficile</i> ribotype 027. DSS (dextran sulfate sodium)-induced <i>in vivo</i> mouse studies with that strain indicate that <b>1</b> is better than vancomycin and fidaxomicin. Thus, micrococcin P2 is a valuable platform to be exploited for the development of new anti-<i>C. difficile</i> antibiotics.